OncoSignal
Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 06:04 UTC. Every row links to its source record.

Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time

A Study Conducted in Subjects With Relapsed/Refractory Multiple Myeloma (MM); to Determine Dose of Afuresertib in Combination With Carfilzomib (Part 1) and to Investigate the Safety, Pharmacokinetic and Clinical Activity of the Combination Compared With Carfilzomib Alone (Part 2)

NCT02235740 · Novartis · PHASE1 · terminated · last registry update 2016-05-04 · Decision brief

No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.

No reason was published

Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.

KindQuoteOur categorySource
StatedThe registry record gives no reason–Registry record, Novartis

Also happening at the time. Not shown to be a cause.

Registry events on other trials of drugs against AKT2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.

What is not public

  • Internal portfolio and board discussions
  • Unpublished trial data and interim analyses
  • Terms of any partner or licence decision